diospyros has been researched along with Breast-Neoplasms* in 3 studies
3 other study(ies) available for diospyros and Breast-Neoplasms
Article | Year |
---|---|
Immunomodulatory Role of Diospyros peregrina Fruit Preparation in Breast Cancer by Utilizing Macrophage Mediated Antigen Presentation and T Helper Cell (Th) Differentiation.
Diospyros peregrina is dioecious plant native to India and belonging to the family of Ebenaceae, is largely utilized in treatment of various ailments. Little has been known about the antitumor activity of Diospyros peregrina with only 1 previous study on Ehrlich Ascites Carcinoma in mice. Therefore, it prompted us to extensively explore the immunomodulatory effect in various cancer forms. The focal point of this study revolves around breast cancer, which is the second most common cancer in the world. In view of the increasing demands for noninvasive treatments, natural plant-based agents open up promising applications in cancer immunotherapy METHODS: CD4. It was found that DFP elevated the proliferation of CD4 Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Breast Neoplasms; Cell Differentiation; Cytokines; Diospyros; Female; Fruit; Humans; Leukocytes, Mononuclear; Macrophages; Mice; T-Lymphocytes, Helper-Inducer | 2023 |
Diospyros Peregrina Fruit Preparation Mediated Immunomodulation of Lymphocytes Isolated From The Blood of Breast Cancer Patients.
Breast cancer is an uncontrolled growth of epithelial cells. The loss of Breast Cancer gene1 (BRCA1) activity due to mutation or down-regulation of gene expression promotes tumorigenesis and increases the risk of breast cancer.. We aimed to pulsate lymphocytes of breast cancer patients and normal individuals, using Diospyros peregrina fruit preparation (DFP) to study the cancer-protective immunity, and the signal transduction processes involved with it. We also investigated the role of DFP in the release of lymphocytic nitric oxide (NO), which is a key tumoricidal agent, known to regulate T-cell proliferation, cytokine production, cell signaling, and apoptosis.. Using Ficoll-Hypaque gradient centrifugation, lymphocytes were isolated from the blood of 12 patients and 12 normal individuals. Cells were treated with or without DFP (2.5 µg/ml) for 48 hours. Both non-stimulated and stimulated cells were then subjected to MTT and NO release assay; following which qPCR was performed to estimate mRNA levels and percentage enrichment of certain genes.. DFP stimulates lymphocytic proliferation (p=0.0118) and release of NO (p=0.01) significantly. DFP also noticeably enhances the expression of T helper (TH) cell 1 specific interferon-gamma (IFNG), interleukin 12 (IL12), T-Box Transcription Factor 21 (TBX21) and signal transducer and activator of transcription 1 (STAT1) genes. DFP treatment significantly increases tumor protective immunity by decreasing the expression levels of TH2 network-specific GATA3 and interleukin 4 (IL4) genes but increasing the expression levels of TH1 network-specific IFNG, IL12, TBX21, and STAT1 genes.. DFP increases the expression levels of TH1 specific network genes which in turn help in evoking tumor protective immunity. Topics: Breast Neoplasms; Diospyros; Female; Fruit; Genes, BRCA1; Humans; Immunomodulation; Interferon-gamma; Lymphocyte Activation; Lymphocytes; Nitric Oxide; STAT1 Transcription Factor; T-Box Domain Proteins; Th1 Cells | 2021 |
In vitro cytotoxicity activity of Diosquinone, a naphthoquinone epoxide.
Diosquinone [1], a naphthoquinone epoxide previously isolated from the root bark of Diospyros mespiliformis (Hostch) and D. tricolor [Ebenaceae] is been assessed for cytotoxicity activity against ten cancer cell lines by standard NIH method. The ethno-pharmacological claim of this plant and the previously observed good antibacterial activity of this compound among the others isolated from this plant suggest its probable cytotoxicity activity. Diosquinone was observed to be very active against most of the cancer cell lines. It shows very good activity against all the cell lines tested with ED50 value ranging between 0.18 microg/ml. against Human Glioblastoma (U373) to 4.5 microg/ml. against Hormone dependent human prostrate cancer( LNCaP). Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diospyros; Drug Resistance, Multiple; Female; Fibrosarcoma; Humans; Lung Neoplasms; Male; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms, Hormone-Dependent; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Tumor Cells, Cultured | 2003 |